Articles

Title	Created Date
MegaPro Medical’s new MRI contrast agent MPB-2043 has completed the first patient admission in Taiwan	2024-12-19
MegaPro (6827)’s new drug MPB-2354 issues a press release on WMIS	2024-10-23
MegaPro (6827) MPB-1734 completes the phase 1 of the last patient, press release	2024-10-23
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.	2024-10-23